Literature DB >> 19996344

Cryptogenic fibrosing alveolitis and lung cancer: the BTS study.

J M Harris1, I D A Johnston, R Rudd, A J Newman Taylor, P Cullinan.   

Abstract

BACKGROUND: The risk of lung cancer is often reported to be increased for patients with cryptogenic fibrosing alveolitis (CFA).
METHODS: Vital status was sought for all 588 members of the British Thoracic Society (BTS) cryptogenic fibrosing alveolitis (CFA) study 11 years after entry to the cohort. Observed deaths due to lung cancer were compared with expected deaths using age-, sex- and period-adjusted national rates. The roles of reported asbestos exposure and smoking were also investigated.
RESULTS: 488 cohort members (83%) had died; 46 (9%) were certified to lung cancer (ICD9 162). The standardised mortality ratio (SMR) was 7.4 (95% CI 5.4 to 9.9). Stratified analysis showed increased lung cancer mortality among younger subjects, men and ever smokers. Using an independent expert panel, 25 cohort members (4%) were considered to have at least moderate exposure to asbestos; the risk of lung cancer was increased for these subjects (SMR 13.1 (95% CI 3.6 to 33.6)) vs 7.2 (95% CI 5.2 to 9.7) for those with less or no asbestos exposure). Ever smoking was reported by 448 (73%) of the cohort and was considerably higher in men than in women (92% vs 49%; p<0.001). Most persons who died from lung cancer were male (87%), and all but two (96%) had ever smoked. Ever smokers presented at a younger age (mean 67 vs 70 years; p<0.001) and with less breathlessness (12% smokers reported no breathlessness vs 5% never smokers; p = 0.02).
CONCLUSIONS: These findings confirm an association between CFA and lung cancer although this relationship may not be causal. The high rate of smoking and evidence that smokers present for medical attention earlier than non-smokers suggest that smoking could be confounding this association.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996344     DOI: 10.1136/thx.2009.121962

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  29 in total

Review 1.  Idiopathic pulmonary fibrosis in East Asian.

Authors:  Changbo Sun; Yanbin Sun; Hui Shen; Chunlu Yang; Shun Xu
Journal:  Intractable Rare Dis Res       Date:  2017-05

Review 2.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  UK asbestos imports and mortality due to idiopathic pulmonary fibrosis.

Authors:  C M Barber; R E Wiggans; C Young; D Fishwick
Journal:  Occup Med (Lond)       Date:  2015-10-28       Impact factor: 1.611

4.  Circulating markers of interstitial lung disease and subsequent risk of lung cancer.

Authors:  Meredith S Shiels; Anil K Chaturvedi; Hormuzd A Katki; Bernadette R Gochuico; Neil E Caporaso; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-08-09       Impact factor: 4.254

5.  Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis.

Authors:  K A Khan; M P Kennedy; E Moore; L Crush; S Prendeville; M M Maher; L Burke; M T Henry
Journal:  Lung       Date:  2014-11-09       Impact factor: 2.584

6.  The surgical outcomes of lung cancer combined with interstitial pneumonia: a single-institution report.

Authors:  Daisuke Taniguchi; Naoya Yamasaki; Takuro Miyazaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Go Hatachi; Tomoyuki Kakugawa; Noriho Sakamoto; Hiroshi Mukae; Takeshi Nagayasu
Journal:  Surg Today       Date:  2017-06-06       Impact factor: 2.549

Review 7.  Lung cancer in never smokers.

Authors:  Ping Yang
Journal:  Semin Respir Crit Care Med       Date:  2011-04-15       Impact factor: 3.119

8.  Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis.

Authors:  Takekazu Iwata; Shigetoshi Yoshida; Kaoru Nagato; Takahiro Nakajima; Hidemi Suzuki; Tetsuzo Tagawa; Teruaki Mizobuchi; Satoshi Ota; Yukio Nakatani; Ichiro Yoshino
Journal:  Surg Today       Date:  2014-11-22       Impact factor: 2.549

9.  Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis.

Authors:  Olivier Bardou; Awen Menou; Charlène François; Jan Willem Duitman; Jan H von der Thüsen; Raphaël Borie; Katiuchia Uzzun Sales; Kathrin Mutze; Yves Castier; Edouard Sage; Ligong Liu; Thomas H Bugge; David P Fairlie; Mélanie Königshoff; Bruno Crestani; Keren S Borensztajn
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

10.  Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.

Authors:  Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-04-17       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.